Maryland denies accused over-stenter’s bid to reclaim medical license
Boston Scientific
HRS 2012 UPDATE: Riata’s survival rate ‘significantly worse’
A study comparing recalled defibrillator leads made by St. Jude Medical (NYSE:STJ) with 1 from rival Medtronic (NYSE:MDT) found 1 St. Jude model’s survival rate to be "significantly worse."
Boston Scientific’s CEO defends the troubled Guidant buyout | Wall Street Beat
Boston Scientific’s (NYSE:BSX) interim CEO Hank Kucheman still believes in the company’s ill-fated acquisition of Guidant Corp., a deal worth $26 billion that was followed by recalls, lawsuits and criminal charges.
Boston Scientific wins FDA nod for latest pacemaker set
Boston Scientific (NYSE:BSX) said the FDA approved the latest set of its pacemakers, including a device designed to treat patients who can’t regulate their heartbeats while exercising.
The Natick, Mass.-based med-tech maker said the watchdog agency granted pre-market approval for its Ingenio and Advantio pacemakers and for its Invive cardiac resynchronization therapy pacer.
MassDevice.com +3 | The top 3 med-tech stories for May 2, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Are Medtronic’s CRM layoffs a sign of a prolonged slump?
Medical device giant Medtronic (NYSE:MDT) confirmed that it will cut jobs from its cardiac rhythm disease management business.
Medtronic spokesman Christopher Garland confirmed news of the layoffs in an email sent to MassDevice.com today, writing that the company’s "CRDM business reduced approximately 220 positions across the US."
MassDevice.com +3 | The top 3 med-tech stories for May 1, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Med-tech trends: Stryker, Medtronic, Covidien, St. Jude, Boston Scientific the most talked about device makers in April
Medical device advisories: moving the needle
In 2005, a flurry of medical device recalls shook the implantable cardiac defibrillator market. The first of these recalls occurred after the former Guidant Corporation (just purchased by Boston Scientific) was forced to admit that a header malfunction of one of their Prism II ICDs had short-circuited and failed to deliver appropriate resuscitating shocks to several patients.
MassDevice.com +7 | The top 7 med-tech stories for the week of April 23, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
BSX ticks up on positive panel vote for Cameron S-ICD
Another heart device won a nod from an FDA advisory panel yesterday when Cameron Health’s subcutaneous implantable cardiac defibrillator won rave reviews from the committee, sending Boston Scientific (NYSE:BSX) shares up a tick today on Wall Street